...
When she first joined the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) in 1980 she worked in the Division of Biochemistry and Biophysics. She was a crucial part of the development of quality control standards for alpha interferon and participated in the reviews of the first alpha interferon products (Schering-Plough’s Intron A and Hoffmann-La Roche’s Roferon). Zoon then became the head of the Cytokine Biology Division (1988–1992) where she coordinated the reviews of further indications for the interferon products, including AIDS-related Kaposi’s sarcoma, genital warts and, more recently, Hepatitis C. Zoon was also involved in the licensing of a third alpha interferon product, Interferon Sciences’ Alferon N. Genentech’s Actimmune (interferon gamma-1b), which was approved in 1990 by Zoon’s group for the rare disorder of chronic granulomatous disease. In 1991, Zoon was in charge of the reviews of granulocyte and granulocyte-macrophage colony stimulating factors (Amgen’s Neupogen and Immunex/Hoechst’s Leukine/Prokine).
...